文献速递前列腺癌

前列腺癌初次冷冻治疗前行3D定位活检的影响

The Impact of Performing a 3D Mapping Biopsy Prior to Primary Cryotherapy for the Treatment of Prostate Cancer.
PubMed 文献 · Urology · 2020-07-23

本研究回顾性分析534例接受前列腺冷冻治疗(PCT)的局限性前列腺癌患者,比较仅经直肠超声引导活检(TRUS)与追加3D定位活检(3DMB)两组。结果显示3DMB组生化失败(BCF)和局部复发率更低,短期并发症更少,而功能结局无显著差异。

要点

  • 两组IPSS和SHIM评分变化无显著差异。

核心结论

  • PCT前进行确认性3DMB可降低BCF和局部复发率,可能因更好的风险分层。
  • 加做3DMB未对并发症率或功能结局产生不利影响。

研究设计与样本

  • 回顾性分析2007年3月至2016年6月间534例接受PCT的局限性前列腺癌患者。
  • 按活检方式分组:仅TRUS组331例,TRUS后追加3DMB组203例。
  • 收集IPSS和SHIM评分,BCF采用Phoenix标准定义。

临床怎么用

  • 对于拟行PCT的局限性前列腺癌患者,可考虑在TRUS活检后追加3DMB以改善风险分层。
  • 3DMB未增加功能损害或并发症风险,可作为术前评估的补充手段。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • 未报告具体的复发率、BCF率及并发症率数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the implications of adding a 3D mapping biopsy (3DMB) prior to prostate cryotherapy (PCT) for the treatment of prostate cancer on the following outcomes: recurrence and biochemical failure (BCF), quality of life outcomes, and complication rates. METHODS: A retrospective analysis of patients treated with either targeted focal therapy, or subtotal CT for localized prostate cancer was performed. The cohort was stratified by patients who had only had a transrectal ultrasound-guided biopsy (TRUS) and those who had undergone 1 additional 3DMB before definitive treatment. Pre- and postprocedural Prostate Symptom Score (IPSS) and Sexual Health Inventory for Men (SHIM) surveys were collected. BCF was defined using the Phoenix criteria. Patients with BCF were re-biopsied. Differences in pre/post changes in IPSS and SHIM scores were examined with Mann-Whitney U tests, binary measures with chi-square tests, and pre/post changes in PSA with t tests. A Kaplan-Meier time to BCF and recurrence analysis is presented. RESULTS: A total of 534 patients underwent PCT following TRUS only (n = 331) and TRUS with subsequent 3DMB (n = 203) between March 2007 and June 2016. No differences were observed in IPSS (P = .60) or SHIM scores drop (P = .06) between groups. PSA drop seemed more pronounced in the TRUS only biopsy group compared to the 3DMB, but again without statistical significance (P = .06). Recurrence rate and BCF were lower in the 3DMB group (P <.01). There was a higher rate of short-term complications detected in the TRUS only group (P = .02). CONCLUSION: BCF and local recurrence rates were lower among patients who underwent a confirmatory 3DMB before PCT, most likely due to better risk stratification in these patients. The addition of a 3DMB did not seem to adversely impact either rate of complications or functional outcomes.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Barqawi A, Pessoa RR, Al-Musawi M, et al. The Impact of Performing a 3D Mapping Biopsy Prior to Primary Cryotherapy for the Treatment of Prostate Cancer. Urology. 2020. PMID: 32711012. doi:10.1016/j.urology.2020.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。